Geneva Court Grants Temporary Moratorium to ObsEva

Rhea-AI Summary

ObsEva SA, a biopharmaceutical company, has been granted a temporary moratorium by the competent court in Geneva, Switzerland, limiting the ability of its creditors to enforce claims against the company. The moratorium will last for four months, during which a commissioner will supervise the company's activities. Dr. Ernest Loumaye, Co-Founder and Chairman of the Board, has undertaken to secure funding to finance operational expenditures. The company is engaged in advanced negotiations for a transaction related to Nolasiban, a compound developed to enhance the live birth rate in women undergoing in vitro fertilization.

Insights

Financial Analyst

The announcement of ObsEva SA's temporary moratorium is a significant event that directly impacts its financial stability and operational future. The moratorium provides the company with a protective shield against creditors, allowing it to negotiate its debts and consider restructuring or liquidation options without the immediate threat of claims enforcement. This is a critical juncture for ObsEva, as it suggests the company is facing substantial financial distress.

From a financial perspective, the 'debtor in possession' funding, if secured, would be pivotal in maintaining the company's operations. This type of financing is typically used in restructuring scenarios to keep a company operational while it works through financial reorganization. The fact that this loan would rank senior to other debts is crucial, as it could impact the recovery rate for other creditors in the event of liquidation or restructuring.

Investors should note that the outcome of the negotiations concerning Nolasiban will likely be a determinant of ObsEva's future value. The successful commercialization of Nolasiban could provide a much-needed revenue stream for the company. However, the inherent uncertainty of such negotiations, especially during a moratorium, adds a layer of risk to the company's prospects.

Legal Expert

The grant of a temporary moratorium by the Geneva court is a legal mechanism that provides breathing space for companies under financial duress. It is designed to temporarily halt the enforcement actions of creditors, thereby preventing the immediate dismantling of the company's assets. The appointment of a commissioner to oversee ObsEva's activities introduces a layer of oversight intended to ensure that the company's actions during the moratorium period are in the best interest of all stakeholders.

The legal implications of this moratorium are profound. It indicates that ObsEva is in a precarious position and is taking steps to protect its interests and possibly negotiate a path to solvency. The role of the court-appointed commissioner is to monitor the company's management decisions, which may include the scrutiny of any potential deals or financing arrangements, such as the 'debtor in possession' funding.

For creditors and investors, the moratorium can be a double-edged sword. While it may lead to a more favorable restructuring outcome, there is also the risk of diminished claims or even losses, particularly if the company proceeds to liquidation. The legal status of the 'debtor in possession' funding as a senior debt also indicates that other creditors may find themselves subordinated in the repayment hierarchy.

Pharmaceutical Market Analyst

The pharmaceutical industry is highly competitive and capital-intensive, with a significant emphasis on research and development (R&D) investments. ObsEva's focus on women's health, specifically on a compound like Nolasiban aimed at improving live birth rates in in vitro fertilization, targets a niche but important market segment with substantial unmet needs.

The success of Nolasiban could be transformative for ObsEva, potentially opening up new revenue streams and partnerships. However, the current financial situation of the company, as indicated by the moratorium, raises questions about its ability to continue funding its R&D effectively and bring the product to market. The company's trajectory will be heavily influenced by the outcome of the ongoing negotiations.

It is also important to consider the broader market implications. If ObsEva is successful in restructuring and bringing Nolasiban to market, it could significantly affect the competitive landscape of fertility treatments. Conversely, if the company is unable to resolve its financial difficulties, the future of Nolasiban and its impact on the market remain uncertain, potentially leaving a gap in a specialized area of women's health.

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

Geneva, Switzerland – 31 January 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it was granted a temporary moratorium (sursis provisoire) by the competent court in Geneva, Switzerland. The Tribunal de première instance of Geneva granted the requested moratorium for a period of four months ending 29 May 2024 and appointed a commissioner (commissaire) to supervise the company's activities during the process. The moratorium limits the ability of ObsEva's creditors to enforce their claims against the company while it evaluates the possibility of a restructuring or orderly liquidation.

ObsEva had requested to be granted a temporary moratorium in December 2023 to enable the company to focus on negotiations and potentially finalize deals that could significantly influence its trajectory.

Dr. Ernest Loumaye, MD, PhD, Co-Founder and Chairman of the Board of Directors, has undertaken to secure "debtor in possession" funding (prêts d'assainissement) to finance ObsEva's operational expenditures until the anticipated conclusion of ongoing business development and financing discussions. The loan, if approved by the court-appointed commissioner, will rank senior to the company's other debts.

Fabien de Ladonchamps, Chief Executive Officer, said: “ObsEva is currently engaged in advanced negotiations for a transaction pertaining to Nolasiban, our compound developed to enhance the live birth rate in women undergoing in vitro fertilization, addressing a substantial unmet medical need. During the moratorium period, ObsEva will continue to advance these ongoing discussions under the supervision of the court-appointed commissioner. ”

About ObsEva

ObsEva is a biopharmaceutical company developing novel therapies to improve women’s reproductive health and pregnancy. ObsEva has established a development program focused on improving in vitro fertilization success rates. ObsEva is listed on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

For further information, please contact:

For general information:                                For investors information:
contact@obseva.ch                                         IR@obseva.ch

 

###

Attachment

• ObsEva - PR Moratorium - 31 Jan 2024_Pdf

FAQ

What is the ticker symbol for ObsEva SA?

The ticker symbol for ObsEva SA is OBSN.

What is the temporary moratorium granted to ObsEva SA?

ObsEva SA has been granted a temporary moratorium by the competent court in Geneva, Switzerland, limiting the ability of its creditors to enforce claims against the company for a period of four months.

Who is overseeing the company's activities during the moratorium period?

A commissioner has been appointed to supervise ObsEva SA's activities during the moratorium period.

What is the purpose of the moratorium for ObsEva SA?

The moratorium limits the ability of ObsEva's creditors to enforce their claims against the company while it evaluates the possibility of a restructuring or orderly liquidation.

What is the company currently negotiating?

ObsEva SA is currently engaged in advanced negotiations for a transaction pertaining to Nolasiban, their compound developed to enhance the live birth rate in women undergoing in vitro fertilization.